Form 4: PMV Pharmaceuticals CFO Michael Carulli Modifies Stock Option Holdings Through Option Exchange Program
SEC Form 4
Chief Financial Officer of PMV Pharmaceuticals, Michael Carulli, participated in an option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a lower exercise price.
Summary
- On August 13, 2024, Michael Carulli, the CFO of PMV Pharmaceuticals, engaged in an option exchange program.
- As part of this program, Carulli's existing stock options for 13,605 shares (exercise price $28.33), 27,200 shares (exercise price $16.29), and 75,000 shares (exercise price $5.70) were cancelled.
- In exchange, Carulli received new options for the same number of shares (13,605, 27,200 and 75,000 respectively), but with a lower exercise price of $1.48 per share.
- The new options have varying vesting schedules, with some vesting immediately and others vesting over time.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The option exchange could be seen as a positive sign that the company is trying to retain and incentivize its CFO, but it could also be interpreted as a sign that the company's stock price has not performed as well as expected.
Positives
- The option exchange program provides the CFO with new options at a significantly lower exercise price, potentially incentivizing him.
- The new options have vesting schedules that align with the company's long-term goals.
Industry Context
Option exchange programs are sometimes used by companies to re-incentivize employees, particularly when the stock price has declined significantly since the original options were granted. This can help retain key personnel and align their interests with those of shareholders.
Comparison to Industry Standards
- Option exchange programs are a relatively common practice in the biotechnology industry, especially for companies with volatile stock prices.
- Similar programs have been implemented by companies such as Novavax and Sorrento Therapeutics to retain and motivate employees.
- The specific terms of the option exchange, such as the reduction in exercise price and the vesting schedule, are generally tailored to the individual circumstances of the company and the employee.
Stakeholder Impact
- Shareholders may view the option exchange as a positive step to retain key management.
- The CFO benefits from a lower exercise price on their stock options.
- Employees may see this as a positive sign that the company is investing in its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/12/2021 | Original grant date of options for 13,605 shares with exercise price of $28.33, vesting monthly from June 12, 2021. |
| 03/10/2022 | Original grant date of options for 27,200 shares with exercise price of $16.29, vesting monthly from March 10, 2022. |
| 05/12/2023 | Original grant date of options for 75,000 shares with exercise price of $5.70, vesting monthly from June 12, 2023. |
| 08/13/2024 | Date of option exchange program where existing options were cancelled and replaced with new options at $1.48 exercise price. |
| 08/13/2025 | Vesting start date for one-third of the new options for 40,805 shares. |
| 02/10/2032 | Expiration date of options for 27,200 shares with exercise price of $16.29. |
| 05/12/2033 | Expiration date of options for 75,000 shares with exercise price of $5.70. |
| 08/13/2034 | Expiration date of new options granted on August 13, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.